MiRXES, Hengrui Pharmaceuticals soar on Hong Kong debut

Mirxes Holding

23/05/2025 03:46

** MiRXES Holding 2629.HK climbs to HK$31.95 on HK debut, up 37.1% from offer price of HK$23.30

** Stock last up 31.8%, outpacing Hang Seng Index's .HSI 0.5% gain and Hang Seng Biotech index's .HSHKBIO 2.3% jump

** Singapore-headquartered micro ribonucleic acid (miRNA) tech co, which specialises in early cancer detection and precision medicine, sells 46.6 mln shares in global offering, raising HK$1.09 bln ($139.2 mln) for R&D, manufacturing, commercialisation of core product

** Jiangsu Hengrui Pharmaceuticals 1276.HK jumps to HK$60.5 on HK debut, up 37.3% from offer price of HK$44.05

** Chinese oncology drug developer sells 224.52 mln H-shares, raising HK$9.89 bln ($1.26 bln) for R&D, constructing  production facilities

** Hengrui's Shanghai stock 600276.SS slips 1.6%

($1 = KH$7.8302)

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))